ViroCyt

Denver, United States Founded: 2012 • Age: 14 yrs Acquired By Sartorius
Virus quantification technology is developed and supplied by ViroCyt.
Annual revenue - Latest available
Total funding $8.7M 2 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About ViroCyt

ViroCyt is a company based in Denver (United States) founded in 2012 was acquired by Sartorius in July 2016. ViroCyt has raised $8.7 million across 2 funding rounds from investors including Sartorius. ViroCyt operates in a competitive market with competitors including Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.

  • Headquarter Denver, United States
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $8.7 M (USD)

    in 2 rounds

  • Latest Funding Round
    $4 M (USD), Series A

    Jun 17, 2015

  • Investors
  • Employee Count
    Not available
  • Acquired by
    Sartorius

    (Jul 15, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ViroCyt

ViroCyt has successfully raised a total of $8.7M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in June 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in ViroCyt

ViroCyt has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sartorius.

All
Institutional
Investor Description Founded Year Domain Location
Laboratory and biopharmaceutical equipment is developed for production processes.
Locked Locked Locked
Premium access

Investor details for ViroCyt

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by ViroCyt

Investments
Premium access

Investment portfolio details for ViroCyt

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - ViroCyt

Premium access

Detailed financials for ViroCyt

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Virocyt Comparisons

ViroCyt Primary company
Description
Virus quantification technology is developed and supplied by...
Location
Denver, United States
Founded Year
2012
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for ViroCyt

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of ViroCyt

ViroCyt operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Quanterix, Biocare Medical, Merck, BioLife Solutions and Telesis Bio, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Assay kits for ultra-sensitive biomarker detection are developed.
Locked Locked Locked
Primary antibodies and instruments for immunohistochemistry are manufactured.
Locked Locked Locked
Merck is engaged in science and technology solutions globally.
Locked Locked Locked
Tissue hypothermic storage and cryopreservation freeze media are developed.
Locked Locked Locked
Online platform offering life sciences reagents and kits
Locked Locked Locked
Portfolio of products and services for life science research and clinical diagnostic markets
Premium access

Detailed competitors of ViroCyt

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Virocyt

Premium access

Complete news archive for ViroCyt

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about ViroCyt

ViroCyt was founded in 2012 and raised its 1st funding round 1 year after it was founded.

ViroCyt is headquartered in Denver, United States. It is registered at Denver, Colorado, United States.

ViroCyt is a funded company, having raised a total of $8.7M across 2 funding rounds to date.

ViroCyt was founded in 2012 in Denver, United States, focusing on biotechnology tools for virus quantification. The Virus Counter 3100 is offered to measure total virus particle concentrations. Applications include vaccine production, protein expression, viral therapeutics, and anti-viral development. Operations center on providing analytical instruments for research and manufacturing in the life sciences sector.

ViroCyt's top competitors include Biocare Medical, Merck and Siemens Healthineers.

ViroCyt has 1 investor. Key investors include Sartorius.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available